Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Objective: To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. Methods: Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-bl...

Full description

Bibliographic Details
Main Author: Coelho, Teresa (author)
Other Authors: Yarlas, Aaron (author), Waddington-Cruz, Marcia (author), White, Michelle K. (author), Sikora Kessler, Asia (author), Lovley, Andrew (author), Pollock, Michael (author), Guthrie, Spencer (author), Ackermann, Elizabeth J. (author), Hughes, Steven G. (author), Karam, Chafic (author), Khella, Sami (author), Gertz, Morie (author), Merlini, Giampaolo (author), Obici, Laura (author), Schmidt, Hartmut H. (author), Polydefkis, Michael (author), Dyck, P. James B. (author), Brannagan III, Thomas H. (author), Conceição, Isabel (author), Benson, Merrill D. (author), Berk, John L. (author)
Format: article
Language:eng
Published: 2022
Subjects:
Physical function
Polyneuropathy
Quality of life
Rare disease
Transthyretin amyloidosis
Online Access:http://hdl.handle.net/10400.16/2665
Country:Portugal
Oai:oai:repositorio.chporto.pt:10400.16/2665

Internet

http://hdl.handle.net/10400.16/2665

Similar Items